Trends in Pharmacological Sciences
PPARs: therapeutic targets for metabolic disease
Section snippets
Nuclear receptor targets for the treatment of metabolic disorders
The three peroxisome-proliferator-activated receptor (PPAR) subtypes, PPAR-γ, PPAR-α and PPAR-δ (also known as PPAR-β), constitute a subfamily of nuclear receptors [1]. These lipid sensors are ‘master’ transcriptional regulators of nutrient metabolism and energy homeostasis that modulate the expression of unique constellations of genes. PPARs form obligate heterodimers with another nuclear receptor, the retinoid X receptor, which bind to peroxisome proliferator response elements (PPREs) that
Adipocytes
PPAR-γ is present in high concentrations in adipocytes [5]. Seminal studies in vitro have demonstrated that this receptor is both necessary and sufficient for adipocyte differentiation, and that it promotes lipid accumulation by adipocytes [6]. The importance of PPAR-γ in adipocyte biology is underscored further by studies in vivo in which adipose-specific ablation of PPAR-γ expression in mice results in adipocyte hypocellularity [7], and heterozygous PPAR-γ knockout mice have reduced adiposity
Lipid metabolism
PPAR-α is expressed highly in liver, heart and skeletal muscle, tissues that extract a high level of their energy requirements from lipids. [50]. During prolonged fasting that results in hypoglycemia, fatty acids are released from fat depots and travel to the liver where they are taken up, oxidized and metabolized into ketone bodies to provide fuel for peripheral tissues. The crucial role of PPAR-α in mediating these metabolic processes and, ultimately, energy homeostasis is demonstrated by the
Pharmacology
Because of its ubiquitous expression and the paucity of selective ligands, PPAR-δ is the least understood PPAR subtype. Nevertheless, early PPAR-δ-selective agonists were found to elevate HDL-C levels in diabetic mice [69], a seminal observation that indicated that PPAR-δ ligands might have beneficial effects on dyslipidemia. Subsequently, the potent PPAR-δ agonist GW501516 (see Chemical names) was shown to increase HDL-C while decreasing elevated TG and insulin levels in obese rhesus monkeys
Selective PPAR-γ modulators
Although the TZDs rosiglitazone and pioglitazone, which are full agonists of PPAR-γ, have significant clinical anti-diabetic efficacy, their use is associated with adverse events including plasma-volume expansion, hemodilution, edema, increased adiposity and weight gain [74]. In addition, TZDs induce cardiomegaly (cardiac enlargement) in some preclinical species 75, 76. These undesirable effects, and the potential to cause congestive heart failure in the considerable subset of diabetic patients
PPAR-α/γ dual agonists and PPAR-α/γ/δ pan agonists
Generally, T2DM patients suffer from both hyperglycemia and dyslipidemia. Clinical studies implicate hyperglycemia in the onset of microangiopathic complications of T2DM, including kidney failure, retinopathy and peripheral neuropathy. However, the major cause of mortality in T2DM patients is atherosclerotic macrovascular disease, which culminates in myocardial infarction. Such cardiovascular disease appears to result, in large part, from diabetic dyslipidemia. Regrettably, although currently
Concluding remarks
The ability of PPARs to mediate many metabolic and therapeutic actions have made them a central focus of pharmacological and genetic research for more than a decade. Through this effort, the PPARs have been shown to coordinately regulate the expression of a vast array of genes including those that control nutrient metabolism, energy homeostasis, insulin signaling, inflammation and cell differentiation. In the clinic, PPAR-γ agonists are effective in treating T2DM patients, and PPAR-α agonists
References (87)
PPARs and the complex journey to obesity
Nat. Med.
(2004)The organization, promoter analysis, and expression of the human PPARgamma gene
J. Biol. Chem.
(1997)Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid activated transcription factor
Cell
(1994)PPAR gamma is required for placental, cardiac, and adipose tissue development
Mol. Cell
(1999)PPARγ mediates high fat diet-induced adipocyte hypertrophy and insulin resistance
Mol. Cell
(1999)PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro
Mol. Cell
(1999)- et al.
Peroxisome proliferator-activated receptor gamma in diabetes and metabolism
Trends Pharmacol. Sci.
(2004) Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes
Metabolism
(1999)Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes
Metabolism
(2003)A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis
Mol. Cell
(2001)
Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes
Eur. J. Pharmacol.
Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages
J. Biol. Chem.
A non-thiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth
Eur. J. Pharmacol.
Negative regulation of the human apolipoprotein A-1 promoter by fibrates can be attenuated by interaction of the peroxisome proliferator activated receptor with its response element
J. Biol. Chem.
Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells
Biochem. Biophys. Res. Commun.
Activation of PPARdelta alters lipid metabolism in db/db mice
FEBS Lett.
Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity
Cell
Benzoyl 2-methyl indoles as selective PPARgamma modulators
Bioorg. Med. Chem. Lett.
Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614
Eur. J. Pharmacol.
MK-0767, a novel dual PPARalpha/gamma agonist, displays robust antihyperglycemic and hypolipidemic activities
Biochem. Biophys. Res. Commun.
The mechanism of action of PPARs
Annu. Rev. Med.
Peroxisome proliferator-activated receptors: nuclear control of metabolism
Endocr. Rev.
The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis
Am. J. Cardiol.
Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle
Proc. Natl. Acad. Sci. U. S. A.
Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones
J. Clin. Invest.
Muscle-specific Pparg deletion causes insulin resistance
Nat. Med.
Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones
J. Clin. Invest.
Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach
J. Clin. Endocrinol. Metab.
The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes
Diabetes
Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes
Diabetes
Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients
J. Clin. Endocrinol. Metab.
PPAR-gamma activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion
Diabetes
Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats
J. Clin. Invest.
Regional adipocity in man
J. Endocrinol.
PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy
Diabetes
Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma
Diabetes
Minireview: The adipocyte–at the crossroads of energy homeostasis, inflammation, and atherosclerosis
Endocrinology
The adipocyte-secreted protein Acrp30 enhances hepatic insulin action
Nat. Med.
The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity
Nat. Med.
Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization
Endocrinology
Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients
J. Clin. Endocrinol. Metab.
Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance
J. Clin. Invest.
Inflammatory pathways and insulin action
Int. J. Obes. Relat. Metab. Disord.
Cited by (625)
Novel thiazolidin-4-one benzenesulfonamide hybrids as PPARγ agonists: Design, synthesis and in vivo anti-diabetic evaluation
2024, European Journal of Medicinal ChemistryEvaluation of fatty acids and carnitine as biomarkers of PFOS exposure in biota (fish and dolphin) from Galveston Bay and the northwestern Gulf of Mexico
2024, Comparative Biochemistry and Physiology Part - C: Toxicology and PharmacologyMolecular origin and biological effects of exercise mimetics
2024, Journal of Exercise Science and Fitness